Concepedia

Author

Gaia Gallo

Eli Lilly (United States)

Also Known As

Elisa Gremese, Evangeline Pierce, G GALLO, G Gallo, G. Gallo, Gabriela Gallo, Gaia Gallo, Gaia  Gallo, Garciela Gallo

138

Publications

2.3K

Citations

27

H-Index

66

Concepts

All Affiliations

Eli Lilly (United States)Icahn School of Medicine at Mount SinaiOregon Medical Research CenterProbity Medical ResearchUniversity of Manchester
GG

About

Gaia Gallo is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

325

2

Engineering

1

1

45

3

Natural Sciences

1

1

21

4

Nursing

1

1

31

5

Biochemistry

1

1

21

Gaia Gallo

×

40

Publications

2K

Citations

26

H-Index

YearCitations

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler,

The Lancet

2019

208

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Andrew Blauvelt, Kim Papp, Alice B. Gottlieb,

British Journal of Dermatology

2019

165

Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study

Simone Veronese, Gaia Gallo, Alessandro Valle,

BMJ Supportive & Palliative Care

2015

154

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Maxime Dougados, James Cheng‐Chung Wei, Robert Landewé,

Annals of the Rheumatic Diseases

2019

118

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Andrew Blauvelt, C. Leonardi, Boni E. Elewski,

British Journal of Dermatology

2020

112

Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( <scp>IXORA</scp> ‐ <scp>PEDS</scp> )

Amy S. Paller, Marieke M.B. Seyger, Gabriel A. Magariños,

British Journal of Dermatology

2020

102

A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis

J.‐P. Ortonne, C. Paul, Enzo Berardesca,

British Journal of Dermatology

2012

93

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

April W. Armstrong, C. Paul, L. Puig,

Dermatology and Therapy

2019

67

Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial

Andrew Blauvelt, Mark Lebwohl, Tomotaka Mabuchi,

Journal of the American Academy of Dermatology

2020

66

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

Linda Stein Gold, Diamant Thaçi, Jacob P. Thyssen,

American Journal of Clinical Dermatology

2023

60

Page 1